Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Knight Therapeutics Inc
KHTRF
Primary Symbol:
T.GUD
Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select...
international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:GUD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Mar 14, 2024 9:14pm
purchase one week out from results
Armoyan purchased of approx $700k in GUD shares - why would that be?
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 14, 2024 7:30am
New Press Release - Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the...
read article.
QMET has 11 claims and 633 hectares Property in Ville-Marie, Quebec Hydrogen Camp
posted Nov 25, 2024 9:00am by
Q Precious & Battery Metals Corp.
-
|
The Company is pleased to discover that their Lorrain claims are now within the new and exciting exploration for hydrogen in the Ville-Marie, Lorrainville and Béarn region of Quebec. The region has undergone a claim staking rush following the ...read more
(8)
•••
wofats
X
View Profile
View Bullboard History
Comment by
wofats
on Mar 13, 2024 6:01pm
RE:RE:BNN next week
of Issuer Holder: Armco Alberta Inc. (Control or Direction) Common Shares 10 - Acquisition or disposition in the public market $402,150 +76,600 vol
...more
(1923)
•••
Possibleidiot01
X
View Profile
View Bullboard History
Comment by
Possibleidiot01
on Mar 12, 2024 2:28pm
RE:BNN next week
stockchase.com, Jason Donville DON'T BUY Knight Therapeutics(GUD-T) 12/03/2024 Years ago, they bought a major company that he owned a lot of
...more
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Comment by
gudisgood
on Mar 12, 2024 6:10am
RE:BNN next week
Interesting! In the short-term, our results and financial situation will be significantly influenced by a couple things: 1) Will the MOH contracts continue coming in? This will significantly affect
...more
(8)
•••
wofats
X
View Profile
View Bullboard History
Post by
wofats
on Mar 09, 2024 4:59pm
BNN next week
Jason Donville This was an analyst who started talking about Paladin Labs in the early days of the stocks rise 2008 or 2009 I believe . Here is a link to some info on his philosophy
...more
(155)
•••
longrun86
X
View Profile
View Bullboard History
Comment by
longrun86
on Mar 07, 2024 10:01am
RE:Raymond James’ Rahul Sarugaser bumped his price target
Analysts make me laugh. If the analyst really believes in the statement they put out regarding Knight as the pre-eminent distributor of phamaceuticals, raising your price target by $0.50 is somewhat
...more
(6)
•••
EbbFlow88
X
View Profile
View Bullboard History
Post by
EbbFlow88
on Mar 07, 2024 7:16am
Raymond James’ Rahul Sarugaser bumped his price target
Raymond James’ Rahul Sarugaser bumped his Knight Therapeutics Inc. target to $7.50 from $7 with an “outperform” rating. The average is $6.56. “GUD is situating itself as the go-to
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Mar 04, 2024 12:45pm
Pharma & Healthcare to be next area of market focus (cnbc)
CNBC – 'Half-Time' trader Joe Taranova, Steve Weiscz and 'Pharma' Jim Leibenthal discuss how biotech & pharma been in slums past years and will be a focus point of markets upcoming
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 29, 2024 7:30am
New Press Release - Knight Therapeutics Announces Launch of Minjuvi® in Brazil
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. Minjuvi® is indicated in combination with...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 28, 2024 7:30am
New Press Release - Knight Therapeutics Inc. Celebrates its First Decade of Success
MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion and growth. Since its inception on February...
read article.
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Feb 27, 2024 9:17am
IBS South America article & chronic kidney disease article
https://finance.yahoo.com/news/south-central-america-irritable-bowel-094300165.html https://www.thelancet.com/campaigns/kidney/updates/kidney-disease-in-latin-america as tenapanor works
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Feb 26, 2024 7:35pm
IBS (potential ( GUD market) in South America market size
The South and Central America irritable bowel syndrome (IBS) diagnostics market is expected to reach US$ 3,880. 91 million by 2028 from US$ 2,470. 61 million in 2020; it is estimated to grow at a CAGR
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Feb 26, 2024 7:31pm
Tenapanor & chronic kidney disease
100 million IBS POTENTIAL people to help with temapanor. also, another use for the product,... Chronic kidney disease! - approximately 4 million people in CANADA! then what about
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario
Options Trading for Retiring: Key Strategies in Balancing Retirement Income